TY  - JOUR 
AU  - Buzón, L.
AU  - Dueñas, C.
AU  - Pedrero, R.
AU  - Iribarren, J.A.
AU  - de Los Santos, I.
AU  - Díaz de Santiago, A.
AU  - Morán, M.Á.
AU  - Pousada Fernández, Guillermo
AU  - Moreno, E.
AU  - Ferreira, E.
AU  - Iglesias, A.
AU  - Martín, C.
AU  - Gómez, J.
AU  - Rodríguez, L.
AU  - Egido, M.
AU  - Sepulveda, M.-A.
AU  - Troya, J.
PY  - 2023
SN  - 1999-4915
UR  - http://hdl.handle.net/20.500.11940/21365
AB  - Dolutegravir (DTG) based dual therapies for treating PLWHIV are a standard of care nowadays. Switching to DTG and lamivudine (3TC) safety and efficacy were proven in TANGO randomized clinical trial. This multicenter retrospective study included 1032...
LA  - eng
KW  - Humans
KW  - COVID-19
KW  - Spain
KW  - Retrospective Studies
KW  - Lamivudine
KW  - Pandemics
KW  - HIV Infections
TI  - Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic
DO  - 10.3390/v15020322
T2  - Viruses
KW  - AS Pontevedra
KW  - CHUP
VL  - 15
ER  -